Immutep’s Efti Shows Promise in Cancer Therapy
Company Announcements

Immutep’s Efti Shows Promise in Cancer Therapy

Immutep (IMMP) has released an update.

Immutep’s latest clinical trial, TACTI-003, shows promising results for its novel immunotherapy, efti, when combined with KEYTRUDA in treating head and neck cancer, with significantly improved response rates, notably in patients with high PD-L1 expression. The combination therapy not only proved to be efficacious but also maintained a favorable safety profile, demonstrating a potential new avenue for cancer treatment without compromising patient safety.

For further insights into IMMP stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskImmutep’s Growth and Advancements Boost Market Visibility
TheFlyImmutep reports Q1 cash receipts from custmers $20,000
TheFlyImmutep announces first-in-human phase I study of IMP761
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App